Merrimack Pharmaceuticals Inc. to Present Preclinical Data at the 24th EORTC-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data on two novel cancer compounds will be presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland November 6 – 9, 2012.